6-K

QuickLinks -- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

October 15, 2004

Commission File Number 001-11145

BIOVAIL CORPORATION
(Translation of Registrant's name into English)

7150 Mississauga Road, Mississauga, Ontario, CANADA, L5N 8M5
(Address of principal executive office and zip code)

Registrant's telephone number, including area code: (905) 286-3000

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ý Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).

Yes o No ý

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).

Yes o No ý

Indicate by check mark whether by furnishing the information contained in this form the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g 3-2(b) under the Securities Exchange Act of 1934.

Yes o No ý

BIOVAIL CORPORATION

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statement on Form S-8 (Registration No. 333-92229) of Biovail Corporation.

INDEX

        Exhibit 99.1 — Material Change Report Dated October 15, 2004

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIOVAIL CORPORATION
Date: October 15, 2004
	By:	/s/  JOHN R. MISZUK JOHN R. MISZUK Vice President, Controller and Assistant Secretary

QuickLinks

BIOVAIL CORPORATION
INDEX
SIGNATURES

EX-99.1

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 99.1

MATERIAL CHANGE REPORT

1.     Name and Address of Company

Biovail Corporation
7150 Mississauga Road
Mississauga, Ontario L5N 8M5

2.     Date of Material Change

October 7, 2004

3.     News Release

A news release was issued by Biovail Corporation over the Business Wire on October 7, 2004 at 4:15 p.m. EST.

4.     Summary of Material Change

Biovail Corporation announced the appointment of senior pharmaceutical industry executive Dr. Douglas Squires as the company's new Chief Executive Officer and that Eugene Melnyk, who has served as the company's Chairman and Chief Executive Officer since December 2001, will continue his full-time duties as Chairman of the Board.

5.     Full Description of Material Change

Biovail Corporation announced the appointment of senior pharmaceutical industry executive Dr. Douglas Squires as the company's new Chief Executive Officer and that Eugene Melnyk, who has served as the company's Chairman and Chief Executive Officer since December 2001, will continue his full-time duties as Chairman of the Board.

As CEO of Biovail Corporation, Dr. Squires will take on operational and general-management responsibilities for Biovail. As Chairman of the Board, Mr. Melnyk maintains his ongoing Board-level responsibilities and will continue, in conjunction with the Board, to set the broad vision and strategy for Biovail's long-term growth and success.

Dr. Squires, 56, has spent the past six years at MDS Inc., where he has held a series of progressively responsible executive positions. For the past three years, Dr. Squires was President and Chief Executive Officer of MDS Pharma Services, a contract research organization that provides drug-discovery and development services to pharmaceutical and biotechnology companies. From 1998-2001, Dr. Squires held the title of President, MDS Panlabs and President, MDS Pharmaceutical Services.

Prior to joining MDS Inc., Dr. Squires spent more than 22 years with The Upjohn Company and Pharmacia Upjohn Inc where he held multiple senior sales, marketing and operational responsibilities in Canada, the United States and the Pacific Rim. Most notably, his roles included Group Vice-President, Infectious Disease Pharma Business (1997-1998); Regional Vice-President, Asia Pacific (1991-1997); Executive Director, Critical Care Business Group (1989-1991); President, The Upjohn Company of Canada (1988-1989); Group Vice-President, Upjohn Canada (1984-1988); and Director, Scientific Affairs, Upjohn Canada (1979-1984). Before

joining Upjohn in 1976, Dr. Squires began his career in the pharmaceutical industry in 1975 with Connaught Laboratories Ltd.

A native of Ontario, Dr. Squires has lived and worked in the United States since 1990. He received his BSc from the University of Toronto and his PhD in biophysics from the University of London, Institute of Cancer Research.

6.     Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A.

7.     Omitted Information

N/A.

8.     Executive Officer

Ken Howling
(905) 286-3000 or send inquiries to ir@biovail.com.

9.     Date of Report

October 15, 2004.

2

QuickLinks

MATERIAL CHANGE REPORT